Buy or sell Mammoth Biosciences stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies
Mammoth Biosciences Stock
CRISPR-Based Disease Detection Platform
About Mammoth Biosciences Stock
Mammoth Biosciences is a developer of a CRISPR platform for diagnostic, genome editing, and protein discovery applications. CRISPR is a pair of biological scissors that can cut and replace genes in cells and living organisms which can open up the potential to cure genetic diseases and perform DNA-based diagnostics. Mammoth aims to discover new types of CRISPR systems that could be used to solve specific biological problems.
Mammoth Biosciences was founded by Janice Chen in 2017 and is based in San Francisco, California. Notable investors include NFX, Mayfield Fund, and Decheng Capital.
Investors
aMoon Fund
Decheng Capital
Mayfield Fund
Lyft, Jawbone, Tonal, Alchemy, Grove Collaborative, Outreach, HashiCorp, MapR Technologies, Fungible, Versa Networks
Pacific 8 Ventures
Plum Alley
Verily
Funding History
| July 2018 | $18.1M |
|---|---|
| January 2020 | $7.4M |
| January 2020 | $36.8M |
| May 2020 | $748K |
| May 2020 | $44.4M |
| July 2021 | $100M |
| July 2021 | $50.0M |
Management
Chief Executive Officer
Trevor Martin
Chief Financial Officer
Elaine Sun
Press
biospace - Mar, 23 2022
marketwatch - Jan, 10 2022
jdsupra - Oct, 29 2021
news - Oct, 5 2021
TechCrunch - Sep, 9 2021
genomeweb - Sep, 9 2021
TechCrunch - Aug, 12 2020
news - May, 20 2020
TechCrunch - May, 20 2020
TechCrunch - Jan, 30 2020
TechCrunch - Mar, 14 2019
TechCrunch - Sep, 4 2018
GenomeWeb - May, 9 2018
TechCrunch - Apr, 26 2018
STAT - Feb, 15 2018
TechCrunch - Sep, 14 2017
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
